Related Experiment Videos
New therapeutic options in the National Cholesterol Education Program Adult Treatment Panel III
1College of Pharmacy, Department of Medicine, The University of Texas Health Science Center, San Antonio, USA.
Insights
New guidelines for treating dyslipidemia expand eligibility for therapy, focusing on low-density lipoprotein (LDL) cholesterol and introducing CHD risk equivalents like diabetes to improve cardiovascular outcomes.
Area of Science:
- Cardiology
- Preventive Medicine
- Public Health
Background:
- Dyslipidemia is a key modifiable risk factor for coronary heart disease (CHD).
- The National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) released updated guidelines for lipid disorder management.
- These guidelines significantly broaden the scope of patients eligible for lipid-lowering therapy.
Purpose of the Study:
- To outline the key changes in the NCEP ATP III guidelines for identifying and managing patients at risk for CHD.
- To emphasize the updated targets for lipid-lowering therapy and the assessment of absolute CHD risk.
- To highlight the new classification of CHD risk equivalents and the role of metabolic syndrome.
Main Methods:
- The NCEP ATP III guidelines establish low-density lipoprotein (LDL) cholesterol as the primary therapeutic target.
- Non-high-density lipoprotein (HDL) cholesterol is identified as a secondary target for patients with elevated triglycerides.
- Assessment of 10-year absolute CHD risk using the Framingham Point Scale is recommended for patients with multiple risk factors.
Main Results:
- The guidelines introduce the concept of CHD risk equivalents, including diabetes and other atherosclerotic diseases.
- A CHD 10-year risk exceeding 20% due to multiple risk factors also defines a CHD risk equivalent.
- New lipoprotein classifications and increased emphasis on metabolic syndrome as a CHD risk marker are presented.
Conclusions:
- The updated NCEP ATP III guidelines aim to improve the identification and management of patients at risk for CHD.
- These recommendations are expected to help more patients achieve lipid goals, thereby reducing cardiovascular morbidity and mortality.
- Strategies for enhancing patient adherence are included to address a major challenge in CHD management.
Abstract:
Coronary heart disease (CHD) is a common, costly, and undertreated disorder in the United States, and dyslipidemia is one of its most important modifiable risk factors. Recently, the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) published updated guidelines for the treatment of lipid disorders, greatly expanding the number of patients eligible for therapy. In the new recommendations, several significant changes have been made in the identification and management of patients at risk for CHD. Although ATP III maintains that low-density lipoprotein (LDL) cholesterol should be the primary target of lipid-lowering therapy, it identifies non-high-density lipoprotein (HDL) cholesterol (total cholesterol minus HDL cholesterol) as a secondary target in patients with elevated triglycerides. Patients with > or = 2 CHD risk factors should now be assessed for 10-year absolute CHD risk based on the Framingham Point Scale to identify those who require more aggressive treatment. The guidelines also designate a new category, CHD risk equivalent, which recognizes that certain patients have the same high risk as those with established CHD. Diabetes is now identified as a CHD risk equivalent, as are other forms of atherosclerotic disease and multiple risk factors comprising a CHD 10-year risk of > 20%. New lipoprotein classifications are given, and increased emphasis is placed on the metabolic syndrome, a constellation of metabolic risk factors, as a marker for CHD risk. Since adherence poses a major challenge in the management of patients with or at risk for CHD, the new guidelines provide physicians with several strategies for increasing patient compliance. The new guidelines should help physicians better identify and manage patients at risk for CHD, help more patients reach their lipid goals, and thereby decrease cardiovascular morbidity and mortality.